Korea Investment CORP Has $25.19 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Korea Investment CORP lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 60,917 shares of the company’s stock after acquiring an additional 880 shares during the period. Korea Investment CORP’s holdings in IDEXX Laboratories were worth $25,186,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Flossbach Von Storch SE grew its position in shares of IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares in the last quarter. William Blair Investment Management LLC grew its position in IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after buying an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in IDEXX Laboratories by 265.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock worth $179,867,000 after acquiring an additional 316,048 shares during the period. Seilern Investment Management Ltd acquired a new position in IDEXX Laboratories in the 4th quarter valued at $113,104,000. Finally, Vontobel Holding Ltd. lifted its position in shares of IDEXX Laboratories by 90.1% during the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after acquiring an additional 198,404 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $415.87 on Friday. The firm has a market capitalization of $33.71 billion, a price-to-earnings ratio of 38.98, a PEG ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average price is $437.07 and its 200-day moving average price is $443.27. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $548.88.

Analyst Ratings Changes

A number of research analysts recently commented on IDXX shares. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.